BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
University of Washington
Seattle, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Washington (26)
2023
-
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology, Vol. 168, pp. 23-31
-
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2020
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2019
2018
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
2017
-
Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci
Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004
-
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Hematological Oncology
2016
2015
-
A global reference for human genetic variation
Nature, Vol. 526, Núm. 7571, pp. 68-74
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Nature Genetics, Vol. 47, Núm. 2, pp. 164-171
-
Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Annals of Oncology, Vol. 26, Núm. 4, pp. 774-779
2014
-
Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel
Nature Communications, Vol. 5
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Journal of Hematology and Oncology, Vol. 7, Núm. 1
2013
2012
-
An integrated map of genetic variation from 1,092 human genomes
Nature, Vol. 491, Núm. 7422, pp. 56-65
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636